Australian Court Dismisses Rusal Suit Over Rio Tinto Alumina Refinery
By Rhiannon Hoyle
An Australian court Thursday dismissed a lawsuit by United Co. Rusal aimed at restoring the Russian aluminum giant's access to supply from one of Australia's largest alumina refineries.
Rusal has a 20% stake in the Queensland Alumina refinery, while Rio Tinto owns 80%.
Rio Tinto in 2022 took over the operation of Queensland Alumina, following sanctions from the Australian government aimed at gumming up Russia's mammoth aluminum industry.
Rusal disagreed with the decision and took legal action to seek to resume its role in the business.
"Rio Tinto can confirm the Federal Court has upheld that Australian government sanctions, in response to Russia's invasion of Ukraine, restrict Rio Tinto from supplying bauxite to Rusal and restrict Queensland Alumina Limited (QAL) from processing bauxite for, and supplying alumina to, Rusal," a Rio Tinto spokesperson said in an emailed statement. "Rio Tinto and QAL plan to continue to operate on this basis for as long as the sanctions continue."
A spokesperson for Rusal couldn't immediately be reached for comment.
Write to Rhiannon Hoyle at rhiannon.hoyle@wsj.com
(END) Dow Jones Newswires
February 01, 2024 01:58 ET (06:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks